Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare CRISABOROLE (Eucrisa) and Pimecrolimus (Elidel) — clinical data, side effects, and patient experiences.
Eucrisa · Other
How it works
12.1 Mechanism of Action Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. T...
Approved for
Elidel · Topical Calcineurin Inhibitor
How it works
Selective calcineurin inhibitor that blocks T-cell activation and cytokine release in the skin without causing skin atrophy like topical steroids.
Approved for
Estimated frequency (%) based on clinical trial data
No data
No specific warnings
No head-to-head clinical studies found for CRISABOROLE vs Pimecrolimus.
CRISABOROLE is a Other, while Pimecrolimus belongs to the Topical Calcineurin Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
CRISABOROLE carries 1 FDA warning. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.